Colonic cancer
Drug research and approvals for colonic cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,194 studies of colonic cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 1,194
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN)NCT07947472 · Not reported · Centre Hospitalier Intercommunal Creteil · starts Nov 9, 2026
- Multicenter Study of SIS Patch in High-risk Colorectal AnastomosisNCT07931300 · Not applicable · Beijing Chao Yang Hospital · starts Jan 1, 2025
- A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of…NCT07919418 · Not reported · Peking Union Medical College Hospital · starts May 24, 2025
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal CancerNCT07913802 · Not reported · Vorarlberg Institute for Vascular Investigation and Treatment · starts Oct 23, 2023
- Development and Utilization of an Integrated Clinical Genomic DatabaseNCT07911267 · Not reported · Samsung Medical Center · starts Dec 6, 2024
- Parastomal Hernia at 1 and 3 Years: Radiological Incidence, Progression, and Impact on Quality of LifeNCT07909148 · Not reported · Region Skane · starts Nov 1, 2026
- KLF4 Epigenetic ModulationNCT07901335 · Not reported · Azienda USL Reggio Emilia - IRCCS · starts Oct 30, 2026
- Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II…NCT07896681 · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Jul 3, 2026
Approved 2
- CapecitabineThymidylate synthase inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
Phase 3 12 of 24
- OxaliplatinDNA inhibitor
- FluorouracilThymidylate synthase inhibitor
- Leucovorin
- IrinotecanDNA topoisomerase I inhibitor
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- AspirinCyclooxygenase inhibitor
- Polyethylene glycol 3350Osmotic laxative
- CelecoxibCyclooxygenase-2 inhibitor
- PanitumumabEpidermal growth factor receptor erbB1 inhibitor
- Folitixorin
- RegorafenibTyrosine-protein kinase ABL inhibitor
- VatalanibStem cell growth factor receptor inhibitor
Phase 2 12 of 61
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- SerplulimabProgrammed cell death protein 1 antagonist
- RG-4733Gamma-secretase inhibitor
- Perifosine
- Antineoplaston A10
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- TopotecanDNA topoisomerase I inhibitor
Phase 1 or earlier 12 of 37
- SelumetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5 other
- DacarbazineDNA inhibitor
- DocetaxelTubulin inhibitor
- FloxuridineThymidylate synthase inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- OmalizumabIg epsilon chain C region inhibitor
- PanobinostatHistone deacetylase inhibitor
- PertuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- ChlorpromazineSerotonin 2a (5-HT2a) receptor antagonist
- TemsirolimusFK506-binding protein 1A inhibitor
- NiclosamideDNA inhibitor
How its trials ended
1,097 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 225 whose ending is known, 31% met their primary endpoint, 10% missed it and 60% stopped early.
- Completed, result not reported42339%
- Ongoing25423%
- Status unknown19518%
- Met its primary endpoint696%
- Stopped: other or unclear626%
- Stopped: enrollment or feasibility363%
- Missed its primary endpoint222%
- Stopped: sponsor or business decision151%
- Stopped: funding91%
- Stopped: lack of efficacy81%
- Stopped: safety4<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA